Exelixis
Sign in to saveExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
OverviewAI-generated
Exelixis is an active operating company established in 1994. It is located in South San Francisco, United States, and is incorporated in Delaware. The organization functions as both a company and a funder.
It operates in the biological products industry, specifically excluding diagnostic substances. Exelixis is listed on the Nasdaq exchange under the ticker symbol EXEL. Its Securities and Exchange Commission Central Index Key is 0000939767, and it follows the Standard Industrial Classification code 2836. The company’s fiscal year ends on January 1.
Synthesized by Vinony from 24 facts across 4 sources: Wikidata, Firecrawl, SEC EDGAR, ROR. Generated from structured data (not the Wikipedia text) and checked against those facts — may still contain errors.
Company
EXEL- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- Nasdaq
- State of incorporation
- DE
- Entity type
- operating
- Fiscal year end
- Jan 1
- Jurisdiction
- US-DE
- Headquarters
- Alameda, US
Research organization · ROR
- Type
- Company, Funder
- Founded
- 1994
- Location
- South San Francisco, United States
- Status
- Active
GRID grid.428377.d · ISNI 0000 0004 0465 1644
Official website
Shaping the Future of Oncology for Patients l Exelixis
Exelixis is an oncology-focused biotech company innovating cancer treatments for life. Find out how we're dedicated to giving more patients hope for the future.
exelixis.com →Link to the official site · 6,652 chars · not written by Vinony
Wikidata facts
- Instance of
- business
- Country
- United States
- Headquarters
- South San Francisco
- Industry
- biotechnology
- Stock exchange
- Nasdaq
- Legal form
- Delaware corporation
- Official website
- www.exelixis.com
Show 3 more facts
- Commons category
- Exelixis
- inception
- 1994-00-00
- social media followers
- 5454
via Wikidata · CC0
~7 min read
Encyclopedic overview
6 sectionsContents
- History
- Finance
- Pricing
- Cabometyx (cabozantinib)
- External links
- References
Innovating medicine brings hope
Excerpted from Wikipedia’s “Exelixis” article, available under the CC BY-SA 4.0 licence.